During the last three decades, pharmacological and psychosocial treatments for schizophrenia have developed rapidly and evolved across countries, resulting in significant effects on patients’ relapse prevention and symptom control.
Because of inadequate consistency in implementation and limited availability and access to different models of effective
treatments, the dissemination of psychosocial interventions as usual practice within mental health services has been slow and patchy